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1 Introduction 
1.1 Oxidative stress in the nucleus 
Free radicals are atoms or molecules that contain unpaired electrons in their outer orbitals 
and this feature makes them to take place in oxidation reactions easily. Free radicals 
include several reactive species such as reactive oxygen species (ROS) and reactive 
nitrogen species (RNS). Reactive species (RS), generated by diverse mechanisms, cause 
oxidative modifications of cellular components. The most prominent feature of RS is their 
high reactivity with biomolecules, causing their denaturation and inactivation. Several 
cellular systems exist to minimize oxidizing effects of RS are called antioxidant systems. 
Oxidative stress is referred to as an imbalance between the RS generation and the 
corresponding antioxidant defenses. Oxidative stress can produce injury by multiple 
pathways that overlap and interact in complex ways [1-3]. 
 
Nucleus is one of the targets of oxidative stress. Nuclear membranes act as a barrier to high 
molecular weight macromolecules and complexes. On the one hand, most oxidants and 
reactive species generated in the cytosol are able to reach the nucleus and chromatin 
through diffusion. On the other hand the nucleus can be a direct target of hydroxyl radical 
(.OH) and hydrogen peroxide (H2O2) formed by ionizing radiation or singlet oxygen (
1O2) 
formation by ultraviolet radiation [4]. 
 
In human beings, tumor cells are frequently subjected to oxidation because of antitumor 
chemotherapy. A number of antitumor drugs act via the oxidation of nuclear material in the 
tumor cell. It is therefore important to know if tumor cells can effectively and precisely 
cope not only with oxidatively induced DNA damage, but also with nuclear protein 
oxidation (5). Free radical production following antitumor chemotherapy may be caused by 
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intratumor drug metabolism or redox cycling reactions [6]. Ultimately, the desirable DNA 
damage that chemotherapy causes in tumor cells is both the consequence of direct reaction 
of cytotoxic drugs with DNA, e.g., alkylating drugs [7], and strand breaks or nucleobase 
oxidation, caused by radical-producing redox cycling in close proximity to the chromatin, 
e.g., anthracyclines [5,6]. Thus the antioxidant defense and repair capacity of tumor cells 
may reduce the efficiency of antitumor chemotherapy and may be a major cause of 
chemotherapy resistance. Adaptation to oxidative stress appears to be one element in the 
development of long-term resistance to many chemotherapeutic drugs and the mechanisms 
of inducible tumor resistance to oxidation are of obvious importance [8].  
 
In the nucleus different structures can be targets of oxidative damage. Radical attack to 
DNA can cause structural alterations such as base pair mutations, abasic sites, strand 
breaks, rearrangements, deletions, insertions and sequence amplification [9]. Numerous 
studies including nuclear proteins and isolated amino acids demonstrated that proteins are 
also susceptible to ROS attack [10]. Oxidative damage on proteins leads to oxidation of 
side chains in amino acid residues, the formation of protein-protein covalent and non-
covalent cross-links and protein fragmentation due to oxidation of the peptide backbone 
[11]. 
 
A limited number of studies refer to modifications of nucleoproteins upon ROS attack.  
Oxidative lesions in free DNA were shown to be higher than in chromatin indicating that 
nucleosomal histone proteins protect DNA from oxidative damage [12,13]. Thus 
association of DNA with histones in chromatin is generally considered to have beneficial 
effects for the maintenance of DNA integrity [14]. Also multiple pathways and repair 
systems repair in vivo oxidative DNA damage. For instance strand breaks are annealed and 
modified bases are removed by a variety of enzymes [15]. 
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1.2 Nuclear proteasomal degradation 
After oxidation of proteins, living cells try to rescue defect polypeptides and restore their 
function. Mammalian cells exhibit only limited direct repair mechanisms and most 
oxidized proteins undergo selective proteolysis. The degradation of proteins is a 
physiological process required to maintain normal cellular function. Therefore, cells have 
developed highly regulated intracellular proteolytic systems responsible for the removal of 
such non-functional proteins before they start to aggregate.  Mammalian cells contain 
several pathways for general protein breakdown, comprising membrane proteases, 
lysosomal cathepsins, calcium-activated calpains, caspases, mitochondrial proteases and 
the proteasomal system [16-19]. Besides all proteolytic systems, the major proteolytic 
system responsible for the removal of oxidized cytosolic and nuclear proteins is the 
proteasomal system [20]. 
  
The proteasome is a large multicatalytic protease that exists in all eukaryotic cells and it is 
responsible for the major part of intracellular proteolysis events [21,22]. Within the 
proteasomal system for cytosol and nucleus, the 20S proteasome is the core particle of the 
proteasome and degrades proteins in an ATP and ubiquitin independent manner. The 20S 
core proteasome is regulated or activated by a number of regulators, including the so called 
19S regulator and 11S regulator.  It is generally believed that the 20S proteasome core 
complex is sufficient for the degradation of oxidized proteins [23-25]. The main accepted 
proteasomal cleavage of the proteins is on the carboxyl side of basic, hydrophobic and 
acidic amino acids (trypsin-like, chymotrypsin-like, and peptidylglutamyl-peptide-
hydrolase activity). 
 
Tumor cells seem to have much higher proteasome activity than do nonmalignant cells and 
most of the extra proteasome appears to be localized in the nucleus [26]. Following 
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oxidation reactions, selective degradation of oxidatively damaged histones might be a 
necessary cellular function for maintaining chromatin integrity. If true, a detailed 
understanding of such mechanisms would be important in antitumor chemotherapy and 
radiation therapy [8]. 
1.3 Poly(ADP-ribose)polymerase-1 (PARP-1) and poly(ADP-
ribosyl)ation reactions 
 
Poly(ADP-ribosyl)ation is a severe post-translational modification of glutamate, aspartate 
and lysine residues of nuclear proteins (acceptor proteins) and represents an immediate 
eukaryotic cellular response to DNA damage as induced by ionizing radiation, alkylating 
agents and oxidants. Poly(ADP-ribosyl)ation is catalysed by poly(ADP-ribose) 
polymerases (PARPs). PARPs use the ADP-ribosyl moiety of NAD+ to covalently modify 
acceptor proteins in successive transfer cycles thus creating linear and/or branched chains 
of poly(ADP-ribose) (pADPr). In the presence of DNA strand breaks, PARP activity and 
the levels of ADPr polymers can be increased by 10-500 fold [27-29], while celular NAD+ 
levels are correspondingly reduced [30]. pADPr, is a homopolymer of ADP-ribose (ADPr) 
units linked by glycosidic bonds  [31,32]. 
 
The polymer is most probably attached onto proteins 
via the γ-carboxy groups of glutamic acid residues 
[33,34]. The polymers of ADPr are degraded rapidly 
by poly(ADP-ribose) glycohydrolase (PARG) in 
vivo, which accounts for their transient nature in 
living cells [28]. PARG splits the unique ribose-
ribose linkages between ADP-ribosyl units of the  
Fig.1.1 PARP and PARG in the poly
(ADP-ribosyl)ation reactions [35]
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polymer, thus creating free ADP-ribose (Fig.1.1) [35]. In addition, branched and short 
polymers are  degraded more slowly than long and linear polymers [36,37]. The 
endoglycosylase activity of PARG is physiologically important, because it is responsible 
for the generation of protein-free ADPr polymers that can  interact with histones and other 
nuclear proteins [38].  
 
Today seven PARP-like enzymes are known with predominantly nuclear localisation. 
Among these 116 kDa PARP-1 is by far the best studied and most abundant member of the 
PARP protein family and appears to be the major poly(ADP-ribosyl)ating enzyme in 
higher eukaryotes after DNA damage [39]. It is not yet known whether other enzymes have 
the ability to catalyse all the reactions necessary to produce branched pADPr polymer, or 
whether they can only synthesize linear polymers [40]. The human gene encoding the 
PARP-1 is termed ADPRT. The ADPRT gene is constitutively expressed at a level 
depending on the type of tissue or cell [41].  
 
 
 
 
 
 
 
 
 
Fig.1.2 Domain structure of PARP-1. Three major proteolytic domains can be broken down into modules 
(A-F). Numbers refer to amino acid positions [Modified from 35] 
 
A B C D E F
DNA-binding domain NAD+-binding domain
Automodification
domain
1 206 234 383 524 656 859 908 988 1014
Active site
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PARP-1 is a highly conserved enzyme that has been detected in most eukaryotes and 
displays a characteristic three-domain structure (Fig.1.2). Its aminoterminal DNA binding 
domain binds to single- or double-strand breaks with high affinity, and induces immediate 
activation of the catalytic centre in the carboxyterminal NAD+-binding domain. The crystal 
structure of NAD+-binding domain shows homology with bacterial toxins that act as mono-
ADP-ribosyl transferases [42]. The enzyme requires the functional DNA-binding domain 
to perform efficient poly(ADP-ribosyl)ation [43,44]. Automodification domain is basic and 
it contains the majority of the 15 glutamic acid residues that would be involved in PARP 
automodification [45,46]. This domain can not serve as an acceptor for ADPr chains unless 
it is associated with the catalytic and DNA binding domain of the enzyme [47]. Several 
proteins have been shown to interact with PARP through its automodification domain. 
These include especially human ubiquitin conjugating enzyme (hUBC9) and histones 
[48,49]. Also PARP-1 is a metalloenzyme that binds zinc molecules specifically [50].  
 
More than 30 nuclear substrates of PARPs have been identified in vivo and in vitro. Most 
of the physiological substrates of poly(ADP-ribosyl)ation reactions are nuclear proteins 
(Tab.1.1). In intact cells, PARP-1 itself is the major acceptor protein, as it catalyses its own 
automodification to complete its shuttling off DNA strand breaks [51].  
 
Importantly, since poly(ADP-ribose) is turned over rapidly due to efficient degradation by 
PARG, the existence of poly(ADP-ribose) in intact cells is not permanent and occurs 
following the DNA strand breaks (Fig.1.3). The total dependence of poly(ADP-
ribosyl)ation on DNA strand breaks strongly suggests that this posttranslational 
modification is involved in the metabolism of nucleic acids [40] identified as protective 
with regard to cell survival and maintenance of genomic stability of cells under genotoxic 
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stress. PARP-1 has also been implicated in the regulation of transcription and proteasomal 
function, playing a crucial role in protein turnover [52,53]. 
 
Potential Function               Acceptor              
 
Modulation of chromatin structure    Histones              
                            PARP               
                            Topoisomerases           
 
DNA synthesis             DNA ligases            
                            DNA polymerases          
                            Topoisomerase II          
 
DNA repair               PARP               
                            DNA ligases            
                            DNA polymerases          
                            Histones              
 
Transcription              RNA polymerases          
                            Fos                 
                            p53                 
 
Cell cycle                Fos                 
                            p53                 
 
Tab. 1.1 Substrates of poly(ADP-ribosyl)ation reactions with their proven functions [modified from 40].   
 
 
 
 
 
 
Fig.1.3 Automodification of PARP and repair of 
DNA strand breaks. The beads on PARP represent  
pADPr [40] 
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Non-covalent interactions between free pADPr and proteins are of importance. Indeed, it 
has been demonstrated that interactions between the polymer and nuclear proteins such as 
p53 and histones are very stable, and could modify the functional properties of these and 
other proteins in living cells [54-56]. 
 
1.4 Histones and their post-translational modifications 
Histones are the chief protein components of chromatin. They act as spools around which 
DNA winds, and they play a role in gene regulation. Without histones, the unwound DNA 
in chromosomes would be very long. There are six classes of histones organized into two 
classes which are core histones (H2A, H2B, H3, H4) and linker histones (H1, H5) [57]. 
 
 
Fig.1.4 Assembly of the core histones 
 into the nucleosome [58].  
 
 
 
Two of each of the core histones assemble to form one octameric nucleosome core particle. 
The linker histone H1 binds the nucleosome and the entry and exit sites of the DNA, thus 
locking the DNA into place and allowing the formation of higher order structure. The most 
basic such formation is the 10 nm fiber or beads on a string conformation. This involves 
the wrapping of DNA around nucleosomes with approximately 50 base pairs of DNA 
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spaced between each nucleosome (also referred to as linker DNA). The assembled histones 
and DNA is called chromatin [58].  
Histones are subject to post-translational modifications by enzymes primarily on their N-
terminal tails, but also in their globular domains. Such modifications include methylation, 
citrullination, acetylation, phosphorylation, sumoylation, ubiquitination, and ADP-
ribosylation. These modifications affect their function of gene regulation. Furthermore, 
histone modifications display alterations during development, the cell cycle, the particular 
chromatin fraction within the same cell type or the variant form within the same histone 
fraction [59]. Poly(ADP-ribosyl)ation is the most dramatic post-translational modification 
of histones in nuclei as well as in nucleosomes [60,61]. The onset of 
poly(ADPribosyl)ation may be accompanied by automodification of PARP-1 and probably 
also by modification of histone proteins. Through these heteromodifications as well as via 
non-covalent binding of histones to the automodified PARP-1 a large and increasingly 
negatively charged, histone–pADPR–PARP-1 complex may be formed at the site of the 
DNA lesion, which eventually dissociates from the DNA. It was shown that, histones H1 
and core histones are the main histones poly(ADP-ribosyl)ated in vivo during DNA repair  
[62,63]. It has been also shown that histones can bind branched polymers of ADPr in a 
non-covalent manner, with the following relative affinity: H1>H2B>H2A>H3>H4 [64]. 
The kinetics of DNA repair are greatly influenced by the presence of histones on damaged 
DNA. The well established poly(ADP-ribosyl)ation of histones in response to DNA 
damage strongly suggests that PARP plays an important role in DNA repair when DNA is 
structured in chromatin [65,66]. Other studies have shown that maximal enzyme activity 
for PARP was associated with trinucleosomes and tetranucleosomes and histone requires 
NAD+ concentrations higher then 100 µM and 1 mM to be poly(ADP-ribosyl)ated . By the 
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way histones stimulate PARP activity up to 20-fold. They act as allosteric activators of the 
enzyme by decreasing the Km of PARP for NAD
+ and by increasing its Vmax [67-69]. 
 
Additionally,  nucleosomal histones are known to protect DNA from free radical-mediated 
damage [70] and are susceptible to oxidative damage in vitro [71]. It is therefore necessary 
to efficiently degrade oxidatively damaged histones in order to maintain genomic integrity. 
Histone proteins are not synthesized only during a limited phase of the cell cycle, but some 
are produced in a constitutive manner, even in nonproliferating cells. Due to the long 
lifespan and low turnover rate of histones, proteolytic reactions are required to be highly 
selective and well regulated [72]. 
 
Core histones demonstrate remarkable sequence conservation, whereas the linker histones, 
especially the histone H1 protein family, diverge significantly in sequence and structure 
[73]. Histone H1 is considered to exhibit a specific role in the transcriptional regulation of 
the expression of particular genes and might be required more for the assembly of specific 
regulatory nucleoprotein complexes than for simply maintaining the nucleosome structure 
of chromatin [74,75]. Thus, in contrast to the core histones, functional impairment of the 
histone H1 protein family by oxidative damage might severely disturb the transcriptional 
regulation of specific genes and therefore essential cellular functions. The higher 
susceptibility of histone H1 to the proteasome both in vitro [71] and in living cells might 
represent an evolutionary advantage by enabling a rapid reconstitution of disturbed 
transcription regulation after acute or chronic oxidative challenge. 
 
1.5   The proteasome-PARP-1 interaction 
In the nucleus of mammalian cells, the rapid activation of the 20S proteasome activity in 
response to oxidative stress is accompanied by and depends on poly(ADP-ribosyl)ation [8, 
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76-79]. In vitro studies revealed that the 20S proteasome interacts with pADPR or 
poly(ADP-ribosyl)ated PARP-1, leading to the specific stimulation of its proteolytic 
activity [80].  This interaction however, was restricted to long pADPR polymers. 
Furthermore no covalent attachment of the poly(ADP-ribose) polymer to the 20S 
proteasome has been demonstrated until now. Therefore, interaction of PARP-1 with the 
20S proteasome requires previous automodification by poly-(ADP-ribosyl)ation, and 
association of the resulting poly-(ADP-ribosyl)ated PARP-1 with the 20S proteasome is 
supposed to occur via non-covalent, but specific binding to pADPR. Subsequent studies 
using different experimental approaches and several cellular models support the notion that 
PARP-1 specifically activates the nuclear proteasome in response to ROS attack [76-78]. 
 
As mentioned above there exist several kinds of PARP enzymes. However, due to the clear 
effects of PARP-1 in in vitro experiments and due to the co-immunoprecipitation 
experiments, it is suggested that PARP-1 is involved in the proteasome activation. 
 
Simultaneously, activation of the nuclear proteasome through non-covalent interaction 
with the automodified PARP-1 results in its enhanced proteolytic activity in close vicinity 
to the poly(ADP-ribosyl)ation-driven histone shuttling event. In addition, heteromodified 
histones might also lead to activation of the proteasome. The proteasome, in turn, would 
rapidly and selectively degrade the oxidatively damaged histones whose proteolytic 
susceptibility is increased due to their oxidative modifications. Furthermore, it was 
hypothesised that oxidatively damaged histones may be excluded from the histone 
shuttling complex, thus being degraded either in DNA bound or soluble form [77]. At this 
time, the damaged DNA should be essentially liberated from associated proteins, thus 
being accessible for the DNA repair machinery as pictured in the PARP-1-BER models. In 
this context, removal of damaged histones from the DNA by the proteasome might even 
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facilitate DNA repair by supporting PARP-1-mediated chromatin decondensation or repair 
complex formation at the damaged sites. Following DNA repair processes, poly(ADP-
ribose) glycohydrolase (PARG), might strip automodified PARP-1 of its pADPR polymer, 
thereby liberating the histone proteins, which could then reassemble into a native 
chromatin structure [78,79]. 
 
1.6 Goals      
Since several lines of evidence exist for a role of the PARP and proteasome interaction in 
pathophysiolgy, I decided to further clarify the role of this interaction in oxidatively 
stressed cells.  For this purpose the following questions were addressed: 
 
1) Characterize the PARP-proteasome-interaction in HT22 cells 
- To investigate the role of selective proteasomal degradation of oxidized proteins in the 
nucleus of HT22 cells  
-  To characterize the role of PARP in the activation of proteasomal degradation. 
- To correlate the mRNA expression of PARP-1 with increased oxidative damage and 
proteasomal degradation. 
 
2) Establish the role of PARP-proteasome-interaction in the ‘chromatin-repair’ 
- To demonstrate the role of PARP-1-proteasome-interaction in the removal of oxidized 
proteins 
- To investigate the role of proteasome-mediated breakdown of oxidized proteins in DNA 
repair following oxidative damage in HT22 cells measured by single strand breaks and 
8OhdG amount 
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3)  Characterize the role of histone oxidation in the PAR-histone shuttling 
-  To see the protein carbonyl formation in isolated histones 
-  To see the difference in the proteasomal degradation of oxidized histones with and 
without poly(ADP-ribosyl)ation. 
-  To observe the poly(ADP-ribosyl)ation of histones following H2O2 treatment. 
 
4.) Modulation of the PARP-proteasome interaction in the senescence process 
- To see the PARP-1 and proteasome protein expressions in young, middle aged and 
senescent fibroblasts 
-  To see the PARP and proteasome activity changes in oxidatively damaged young, 
middle aged and senescent cells. 
-  To prove the main role of PARP in proteasome activation in young and senescent cells. 
 18 
 
 
2     Materials and Methods 
2.1 Chemicals  
Antibodies:  
Anti-Dinitrophenyl (DNP)-rabbit-IgG antiserum (Sigma-Aldrich D9656)  
Monoclonal Anti-Rabbit IgG (γ-chain specific), Peroxidase Clone RG-96 (Sigma-Aldrich 
A1949) 
20S proteasome ‘core’ subunits, rabbit polyclonal antibody (Biomol PW8155)  
Anti-poly(ADP-ribose), mouse monoclonal antibody (Biomol SA-216) 
PARP antibody, rabbit polyclonal (Cell Signaling 9542) 
Histone H4 antibody (Cell Signaling 2592) 
Goat Anti-Rabbit IgG, H & L Chain Specific Peroxidase Conjugate (Calbiochem 401315) 
Rabbit Anti-Mouse IgG, H & L Chain Specific Peroxidase Conjugate (Calbiochem 
402335) 
 
Chemicals: 
20xLumiGLO Reagent and 20x Peroxide (Cell Signaling 7003) 
PageRuler Unstained Protein Ladder (Fermentas SM0661) 
iScript cDNA Synthesis Kit (Biorad 170-8890) 
Qiagen DNeasy Blood Tissue Kit, Cat no. 69504 
IQ SYBR Green Supermix (Biorad 170-8882) 
Highly Sensitive 8-OhdG Check ELISA kit (JaICA, KOG-HS10E) 
Bio Rad Protein Assay (Bradford) (Biorad 500-0006) 
Bio Rad, DC Protein Assay, Reagent A (Biorad 500-0113) 
Bio Rad, DC Protein Assay, Reagent S (Biorad 500-0115) 
Bio Rad, DC Protein Assay, Reagent B (Biorad 500-0114) 
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[carbonyl-14C]Nicotinamide adenine dinucleotide, ammonium salt (GE Healthcare 
CFA372) 
PARP-1 human recombinant, expressed in E.coli (Sigma-Aldrich P0996) 
Nonidet P-40, Octylphenolpoly(ethyleneglycolether) (Roche 11 332 473 001) 
 
All the other chemicals used were obtained from Sigma. 
 
2.2  Experiments in cell culture 
2.2.1 Cell line propagation                                                                                                                             
HT22 cells (mouse hippocampal neuronal cells) were cultured at 37 °C and 5% CO2 under 
standard conditions. A high glucose DMEM medium containing an additional 0.35% 
glucose was used supplemented with 10% fetal calf serum (FCS), 1% 
penicillin/streptomysin and 1% glutamine. Cells initially were seeded at a density of 0.2 
x106 cells/ml and then grown for three days to a density of 3x106 cells/ml.  
2.2.1.1 Cell treatments with inhibitors and H2O2            
Firstly, cells were treated with different concentrations of hydrogen peroxide (H2O2) for 
various time periods (Tab.2.1). The concentrations and time periods were chosen according 
to the MTT viability test results (Fig.3.1). Used concentrations and time periods provided 
viability higher than 75%.  
H2O2 solutions were prepared as: 
1M stock solution: 114 µl 30% H2O2 + 886 µl PBS with Ca & Mg 
0.25 mM: 7.5 µl stock solution / 30 ml PBS with Ca & Mg 
0.50 mM: 15 µl stock solution / 30 ml PBS with Ca & Mg 
0.75 mM: 22.5 µl stock solution / 30 ml PBS with Ca & Mg 
1.00 mM: 30 µl stock solution / 30 ml PBS with Ca & Mg 
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H2O2 concentrations 
(mM) for 30 min 
0.00 – 0.25 – 0.50 – 0.75 – 1.00 
Time durations (min) 
with 1.00 mM H2O2 
0 – 10 – 20 – 30 – 40 – 50 – 60 
   
Tab.2.1 H2O2 concentrations and time durations for the incubation of HT22 cells 
 
Incubations with several inhibitors were done as indicated in the Tab.2.2. All incubations 
were carried in 3 ml PBS with Ca & Mg. 
 
Chemical Function Concentration 
(Stock solution) 
End 
concentration 
Duration of 
pretreatment 
3-ABA PARP-1 inhibition 0.5 M in PBS 5 mM 30 min 
PJ-34 PARP-1 inhibition 4 mM in PBS 40 µM 30 min 
LC 20S proteasome 
inhibition 
1328 µM in 
PBS 
20 µM  30 min 
 
Tab.2.2 Inhibitors used in PARP-1 and 20S proteasome inhibition with HT22 cells. 
 
2.2.1.2  Isolation of nucleus 
Following the incubations, the cells were washed once with ice-cold PBS, scraped with 
ice- cold PBS into an eppendorf tube and centrifuged at 2000 rpm for 5 min at 4°C. The 
supernatants were removed and lysis buffer (Tab.2.3) was added with the final volume 
equivalent to five times the pellet volume, incubated on ice for 10 min. 10% NP-40 was 
added in the amount necessary to obtain a final concentration of 1%, mixed by pipetting, 
and centrifuged at 15000 rpm for 1 min at 4°C. Supernatants were removed and discarded. 
The same volume of extraction buffer (Tab.2.4) as lysis buffer was added and incubated on 
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ice for 20 min with vigorous vortexing every 5 min, centrifuged at 15000 rpm for 10 min at 
4°C and the supernatants were used for the assays [81]. 
                                                                                                                    
Lysis buffer 
10 mM HEPES, pH 7.8 
10 mM KCl 
2 mM MgCl2 
0.1 mM EDTA 
Tab. 2.3     Lysis buffer used in the nuclear extraction of HT22 cells 
 
Extraction buffer 
50 mM HEPES, pH 7.8 
50 mM KCl 
300 mM NaCl 
0.1 mM EDTA 
10% Glycerol 
Tab. 2.4    Extraction buffer used in the nuclear extraction of HT22 cells 
 
2.2.1.3  Protein amount measurements 
Bradford Assay 
In 96-well plate, 4 µl of standard or sample solutions were incubated for 5 min with 200 µl 
of Bio-Rad reagent and absorbance was measured using 590 nm filter (Reference filter; 
750 nm) with UV/Vis-Multiwell reader. The amounts of proteins were calculated 
according to the standad curve as mg protein/ml [82].  
 
Lowry Assay 
Reagent A, S and B were obtained from Bio-Rad. Reagent A’ was prepared freshly by 
shaking. Reagent A and S as 1/50 (v/v). In 96-well plate, 5 µl of standard or sample 
solutions were incubated with 25 µl of Reagent A’ and 200 µl of Reagent B for 15 min and 
absorbance was measured using 750 nm filter (Reference filter; 750 nm) with UV/Vis-
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Multiwell reader. The amounts of proteins were calculated according to the standad curve 
as mg protein/ml [83]. 
    
2.2.2 MTT viability test  
MTT test was performed to determine treatment parameters in HT22 cells following the 
conditions showed in Tab.2.1. The concentration higher than 1.00 mM of H2O2 for 30 min 
and the duration longer than 60 min with 1.00 mM H2O2 caused a cell death higher than 
75%. In the viability test, 2x106 cells were used in 60 mm petri dishes. Following the 
indicated treatments, incubation solutions (generally in PBS) were discarded. 100 µl of 
MTT solution was mixed with 3 ml DMEM and incubated for 2 h at 37 °C and 5% CO2. 
Following this incubation period, medium was discarded and 1 ml of solubilizing reagent 
was added, incubated for 5 min and the absorbance of 50 µl of supernatant were measured 
in the 96-well plate using 590 nm (Reference filter; 660 nm) with UV/Vis-Multiwell 
reader. Calculations were done related to te absorbance of control samples which was 
equaled to 100%.                                                                                                                       
MTT (Thiazolyl blue tetrazolium bromide) 10 mg MTT / 1 ml PBS 
Solubilizing reagent 10 g SDS / 99.4 ml DMSO + 0.6 ml acetic acid 
 
Tab. 2.5     Solutions for MTT viability assay 
 
2.2.3 Proteasome activity analysis  
Following the treatments of HT22 cells in Tab 2.1 indicated conditions, nuclear extracts 
were obtained as described in 2.2.1.2 and these extracts were used in proteasome activity 
analysis.   The design of one well in 96-well plate was done as shown in Tab. 2.6. The 
reaction was carried out at 37 °C for 30 min. As a result of this reaction, chymotrypsin-like 
activity of 20S proteasome was determined. The fluorescence of the liberated MCA was 
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monitored at 365 nm excitation and 460 nm emission wavelengths. The amount of 
substrate degradation is calculated using the calibration curve prepared with free MCA 
standards as nmol MCA / mg protein x min. 
Content Amounts 
Nuclear extract 10 µl 
Proteolysis buffer 33.3 µl 
DTT  0.2 µl 
H20 45.5 µl  
2-Deoxy-D-glucose  9 µl 
Hexokinase 12 µl 
Suc-LLVY-MCA 10 µl 
Tab. 2.6     One well design for the proteasome activity analysis  
                                                                                                                       
Proteolysis buffer 0.45 M Tris, 90 mM KCl, 15 mM Mg(CH3COO)2 · 4 
H2O, 15 mM MgCl2 x 6H2O (pH 8.2) 
DTT (Dithiothreoitol) (1M) 0.309 g DTT / 2 ml ice-cold H2O 
Suc-LLVY-MCA (2 mM) 10 mg / 6.55 ml DMSO 
2-Deoxyglucose (200 mM) 0.33 g / 5 ml H2O 
Hexokinase 1 mg / 1 ml H2O 
MCA standards 1.stock (100 mM): 88 mg / 5 ml DMSO 
2.stock (100 µM): 10 µl 1.stock + 9.99 ml dilution 
buffer (1/3 diluted proteolysis buffer containing 10% 
DMSO) 
Standards: 
10 µM: 100 µl 2.stock + 900 µl dilution buffer 
  5 µM:   50 µl 2.stock + 950 µl dilution buffer 
  2 µM:   20 µl 2.stock + 980 µl dilution buffer 
  1 µM:   10 µl 2.stock + 990 µl dilution buffer 
0.5 µM:     5 µl 2.stock + 995 µl dilution buffer  
 
Tab. 2.7     Solutions for proteasome activity analysis 
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2.2.4 Immunoblot analysis 
Following the treatments of HT22 cells with 1.00 mM H2O2 in the 0-30-50 min durations, 
nuclear extracts were obtained as described in 2.2.1.2 and whole cell lysates were obtained 
at 4 ºC using 10mM Tris HCl pH 7.5 buffer containing 1 mM Pefabloc, 0.9% NP-40, 0.1% 
SDS. Nuclear extracts and whole cell lysates were blotted separately. The protein 
concentrations of the nuclear extracts were determined according to Bradford [82] while 
the protein concentrations of whole cell lysates were determined according to Lowry [83]. 
30 μg of total protein in reducing Laemmli-buffer (0.25 M Tris pH 6.8, 8% SDS, 40% 
glycerol, 0.03% bromophenol blue) were denatured at 95 °C for 5 min and applied to SDS-
PAGE of 12% (w/v) acrylamide for proteasome and of 7.5% (w/v) acrylamide for PARP-
1, followed by electrophoresis and blotting onto nitrocellulose membrane according to 
standard procedures. Immunodetections were performed with the following antibodies: 
rabbit polyclonal anti-PARP (Cell Signaling) at 1:1000 dilution, rabbit polyclonal anti-20S 
proteasome ‘core’ subunits at (Biomol) 1:1000 dilution. After exposure to peroxidase-
coupled secondary antibodies (Calbiochem), membranes were developed using Lumi-Light 
western blotting substrate (Cell Signaling). 
 
2.2.5 qPCR analysis 
Following the treatments of HT22 cells with 1.00 mM H2O2 for the time periods indicated 
in Tab. 2.1, cells were lysed and total RNA was isolated using the Qiagen RNeasy Mini 
Kit RNA isolation was carried out according to the manufacturer’s protocol as follow: 
5x106 cells were disrupted by adding 350 µl buffer RLT. Cell lysates were collected with a 
cell scraper and mixed by pipetting. 350 µl of 70% ethanol was added to the lysate and 
mixed well by pipetting. The samples were pipetted into a RNeasy spin column, 
centrifuged for 15s at 14000 rpm. Flow through was discarded, 700 µl of buffer RW1 was 
pipetted into the column and centrifuged for 15s at 14000 rpm to wash. Flow through was 
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discarded, 500 µl of buffer RPE was pipetted into the column and centrifuged for 15s at 
14000 rpm to wash. Flow through was discarded, 500 µl of buffer RPE was pipetted into 
the column and centrifuged for 3 min at 14000 rpm to wash. Spin column was transferred 
in a new collection tube, 50 µl of RNase-free water was pipetted directly onto the 
membrane, centrifuged for 1 min at 14000 rpm to elute the RNA. The amount and purity of 
the extracted RNA were determined via spectrophotometry in a Smartspec 3000 (BioRad). 
An iScript cDNA synthesis kit and 1 μg of RNA were used for cDNA synthesis. 
Quantitative real-time PCR was performed using a BioRad iCycler 3.0 and the BioRad IQ 
Sybr Green reaction mixture. The sequences of primers used in this work were as follows: 
mouse PARP-1 left: TGAAAGGGACGAACTCCTATT, mouse PARP-1 right: 
GGCATCTGCTCAAGTTTGT-TA.  
 
2.2.6 Protein carbonyl measurement in cell lysates 
Protein carbonyl amounts were measured in the cell lysates 0.5-2-3 h after 1.00 mM H2O2 
treatments of HT22 cells for 30 min. These post incubations following H2O2 treatment of 
the cells were carried out in DMEM medium. This experiment was to determine the 
recovery from carbonyl formation by the time and the effects of 3-ABA and LC on this 
recovery.  Carbonyls were determined in cell lysates (4 mg/ml in lysis buffer) by an ELISA 
as introduced by Buss et al. [84]. According to the protein amount used, different 
concentrations of BSA standard solutions were prepared for standard curve. The onset of 
the experiment was as follow: 
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15 µl of samples or standards + 45 µl of fresh DNP solution 
Incubated for 45 min at room temperature in the dark with continuous shaking 
 
5 µl of the incubation solution + 1 ml coating buffer 
 
3x200 µl were loaded into 96-well Nunc Immuno Plate Maxisorb 
Incubated overnight at 4 °C 
 
Samples were discarded which are not absorbed onto the plate 
Plates were washed with PBS to remove excess DNP 
 
250 µl of blocking solution for 1.5 h at room temperature in the dark  
 
200 µl anti-DNP antibody for 1 h at 37 °C 
 
Washed three times with PBS containing 0.1% Tween 20 
 
200 µl anti-rabbit-IgG-POD-antibody for 1 h at room temperature in the dark 
 
 Washed three times with PBS containing 0.1% Tween 20 
 
200 µl substrate solution for 15 min at 37 °C 
 
The reaction was stopped with 100 µl of 2.5 M H2SO4 
 
Absorbance was measured at 492 nm wavelength using a microplate reader (BioTek 
Instruments EL 340). 
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Lysis buffer 200 µl of 500 µM HEPES + 40 µl of 250 
mM DTT + 9.76 ml H2O 
DNP buffer 6 M Guanidinehydrocloride + 0.5 M 
KH2PO4 pH 2.5 
DNP solution 10 mM = 2 mg/ml in DNP buffer 
Coating buffer 0.71 g Na2HPO4 + 0.6 g NaH2PO4 + 4.1 g 
NaCl in 500 ml H2O (pH 7.0) 
Blocking solution 10 ml 11 mg/ml BSA + 90 ml PBS 
containing 0.1% Tween 20 
Developer 0.71 g Na2HPO4 + 0.5 g citric acid in 100 ml 
H2O  
Anti-DNP-antibody (rabbit) (Sigma D-
9656) 
1:1000 dilution in blocking solution  
Anti-rabbit-IgG-POD-antibody (Sigma 
A-1949, monoclonal) 
1:10000 dilution in blocking solution   
Substrate solution (60 mg tablet o-
phenylenediamine, Sigma P-1063) 
60 mg / 5 ml in developer          1 ml + 19 
ml developer + 8 µl H2O2 
Oxidized BSA 50 mg/ml in 50 mM hypochloric acid for 2 
h at room temperature incubation  
 
Tab. 2.8     Solutions for protein carbonyl measurement by ELISA 
 
2.2.7 Comet Assay 
HT22 cells were seeded in 12-well plate as 50000 cells/well. Confluent cells were used in 
the experiment. Object slides were covered with normal melting agarose and kept until use. 
Low melting agarose was boiled in microwave until dissolved, aliquoted in 2 ml eppendorf 
tubes and kept on the 40 °C heating block. Following the incubations, cells were 
trypsinized and 400 µl of 1% LMA added onto the wells. 70 µl of the suspension pipetted 
onto the covered object slides and covered each with cover glass and kept at 4 °C for 15-20 
min. Slides were incubated in the Triton-X 100 solution for 1h at 4°C and in the 
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electrophorese buffer for 40 min at 4°C. Electrophoresis was run 25V, 300 mA for 30 min. 
Slides were washed three times with neutralizing buffer, fixed for 15 min with fixative and 
comets were determined with fluorescence microscopy. 
Treatment design 
Dose dependent DNA damage: 0.1-0.2-0.3-0.4-0.5 mM H2O2 in PBS with Ca&Mg for 30 
min.  
Recovery following H2O2 treatment: Incubation with 0.4 mM H2O2 in PBS with Ca&Mg 
for 30 min        Incubation in medium for 0-1-2-3-4-6-24 hours. 
Effects of LC, 3-ABA and PJ-34 on the recovery: 30 min incubation with 20 µM LC, 5 mM 
3-ABA, 40 µM PJ-34 in PBS with Ca&Mg (for control samples, incubation with PBS with 
Ca&Mg)                 Incubation with 0.4 mM H2O2 in PBS with Ca&Mg for 30 min                   
Incubation in medium for 3 hours.                                                            
    
Normal melting (NMA) and low-
melting agarose (LMA) 
1% in PBS 
PBS 8 g NaCl + 0.2 g KCl + 0.2 g KH2PO4 + 1.44 g Na2HPO4 in 
1000 ml H2O (pH 7.4). 
Lysis solution 146 g NaCl + 37 g Na2EDTA + 1.2 g Tris Base in 1000 ml H2O 
(pH 10). 
Triton-X 100 solution 1% in lysis solution (prepared fresh) 
Electrophoresis solution 12.1 g NaOH + 0.37 g Na2EDTA in 1000 ml H2O 
Neutralizing solution  48.5 g Tris base in 1000 ml H2O (pH 7.5) 
Fixative 100% methanol 
 
Tab. 2.9  Solutions for COMET assay 
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2.2.8 8-OHdG analysis 
Treatment design 
20 µM LC and 0.4 mM H2O2 at the end concentrations were used in the incubations. 
Subconfluent HT22 cells in petri dishes; 
-30 min in PBS with Ca&Mg + 30 min in PBS with Ca&Mg                 The cells were 
scraped 
-30 min in PBS with Ca&Mg + 30 min in PBS with Ca&Mg + 3h in medium               The 
cells were scraped 
-30 min in PBS with Ca&Mg + 30 min H2O2                         The cells were scraped 
-30 min in PBS with Ca&Mg + 30 min H2O2  + 3h in medium              The cells were 
scraped 
-30 min in LC + 30 min H2O2              The cells were scraped 
-30 min in LC + 30 min  H2O2  + 3h in medium                      The cells were scraped 
 
DNA extraction was done according to the procedure described in Qiagen DNA extraction 
kit with spin-column protocol as follow: 5x106 cells were scraped and centrifuged for 5 
min at 300xg. The pellet was resuspended in 200 µl PBS + 20 µl proteinase K. 200 µl 
buffer AL was added, mixed throughly by vortexing and incubated at 56 °C for 10 min. 
200 µl ethanol was added to the sample and mixed throughly by vortexing. The mixture 
was pipetted into the Dneasy Mini spin column placed in a 2 ml collection tube, 
centrifuged at 8000 rpm for 1 min, the flow through and collection tube were discarded. 
Dneasy Mini spin column was placed in a new collection tube, 500 µl buffer AW1 was 
added, centrifuged for 1 min at 8000 rpm, flow through and collection tube were discarded. 
Dneasy Mini spin column was placed in a new collection tube, 500 µl buffer AW2 was 
added, centrifuged for 1 min at 14000 rpm to dry the Dneasy membrane, flow through and 
collection tube were discarded. Dneasy Mini spin column was placed in a new collection 
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tube, 200 µl buffer AE was pipetted directly onto the Dneasy membrane, incubated at 
room temperature for 1 min, centrifuged for 1 min at 8000 rpm to elute the DNA. For 8-
OHdG analysis, highly sensitive 8-OHdG Check ELISA kit was used that was obtained 
from JaICA (Japan Institute Control of Aging) and 50 µg of DNA was used in the assay. 
50µl standards and samples were added into 96-well plate and incubated overnight at 4 °C 
with 50 µl of primary antibody which is a monoclonal antibody specific for 8-OHdG. The 
contents were poured off. Following washing steps, 100 µl of secondary antibody which is 
HRP-conjugated were added into each wells and incubated for 1h at room temperature. 
Following washing steps, 100 µl of 3,3’,5,5’-tetramethylbenzidine + hydrogen 
peroxide/citrate chromatic substrate solution was added into wells and incubated for 15 
min at room temperature. 100 µl of 1 M phosphoric acid reaction terminating solution was 
added and the absorbance was measured at 450 nm wavelength using a microplate reader 
(BioTek Instruments EL 340). In the principle of the assay, the special plate was precoated 
with 8-OHdG. Therefore higher concentrations of 8-OHdG in the sample solution led to 
reduced binding of the antibody to the 8-OHdG on the plate and decreases the absorbance 
at the end. 8-OHdG amounts were calculated as ng/mg DNA according to the standard 
curve. 
              
2.2.9 PARP activity measurement 
Cellular PARP activity was detected using cellular ELISA method [85]. Cells were seeded 
in 96-well plates pretreated with 20 µM LC, 5 mM 3-ABA and 40 µM PJ-34 and 
stimulated with 0.4 mM H2O2. After treatment for 30 min at 37
oC, plates were rinsed with 
200l PBS. Cells were fixed in 10% ice-cold TCA (100 l/well) at -20oC for 10 minutes, 
then dehidrated by successive 10 min washes in 100l prechilled 70%, 96% and 100% 
ethanol at -20oC. After 3x5 min rinses with PBS, endogenous peroxidase activity was 
blocked by 15 min incubation in 0.5% hydrogen peroxide/methanol. After washing with 
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PBS, plates were blocked in 5% bovine serum albumin (BSA) in PBS-Triton X-100 for 60 
min at 37oC. BSA solution was then aspirated and cells were incubated with 10H 
monoclonal anti-poly(ADP-ribose) antibody diluted 1:5000 in 1% BSA/PBS- Triton X-100 
for 2 h at 37oC. After three washes with PBS-Triton X-100, samples were incubated with 
peroxidase conjugated anti-mouse IgG (Calbiochem) diluted 1:300 in 1% BSA/PBS- 
Triton X-100 for 90 min at 37oC. Cells were then washed three times with PBS Triton X-
100 and reaction was developed with Amplex Red substrate. Fluorescence was measured 
at 530 nm excitation and 590 nm emission wavelength with a microplate reader.  
 
2.3  In vitro experiments 
2.3.1 Histone oxidation 
Histone stock solutions were prepared in different concentrations as follow according to 
the experiment: 
Protein carbonyl ELISA: 4.4 mg histone / ml PBS            4 mg/ml end concentration 
Protein carbonyl western blot: 9.7 mg histone / ml PBS            8.8 mg/ml end concentration 
Fluorescamine: 2.2 mg histone / ml PBS            2 mg/ml end concentration 
PAR of histones: 9.7 mg histone / ml PBS            8.8 mg/ml end concentration 
 
The histone solutions were dialyzed against PBS 2x3 h and overnight before and after 
oxidation. Oxidation process was carried out for 2h at 25 °C with 500 rpm shaking. 330 
mM stock H2O2 solution was used to prepare 0-1-5-10-15-20-30 mM end concentrations.  
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2.3.2  Protein carbonyl measurement in isolated histones 
2.3.2.1  ELISA 
0-5-10-15-20-30 mM oxidized histones were used in the experiment. The experimental 
procedure was carried out same as described in 2.2.6 without any lysis procedure.  
 
2.3.2.2  Western blot 
50 µl of histone samples oxidized with 0-10-20 mM H2O2 mixed with 25 µl nonoxidized 
nuclear extract (prepared as described in 2.2.1.2), 50 µl 2 mM NAD+ (Sigma N8410) 
solution and 125 µl reaction buffer including 300 mM sucrose and 10 mM HEPES. The 
reaction mixture was incubated for 15 min at 37°C, centrifuged 720xg for 5 min. 45 µl of 
supernatants mixed with 15 µl reducing Laemmli-buffer prepared as described in 2.2.4 and 
were denatured at 95 °C for 5 min and applied to SDS-PAGE of 10% (w/v) acrylamide, 
followed by electrophoresis and blotting onto nitrocellulose membrane according to 
standard procedures. 
 
Following the electroblotting step, the membrane were equilibrated in TBS (100 mM Tris, 
150 mM NaCl, pH 7.5) containing 20% methanol for 5 min, washed in 2N HCl for 5 min, 
incubated with 10 mM DNPH solution for 5 min, washed 3x5 min in 2N HCl and washed 
5x5 min in 50% methanol. DNPH treated membrane was blocked with 5% non-fat dry 
milk in TBST (TBS contains Tween 20) for 1h at room temperature with constant 
agitation. Blocked membrane was washed 3x5 min with TBST and incubated with rabbit 
anti-DNP antibody freshly diluted 1:25000 in 5% non-fat dry milk/TBST for 1h at room 
temperature with constant agitation. Blotted membrane was washed 3x5 min with TBST 
and incubated with anti-rabbit-IgG-POD-antibody freshly diluted 1:5000 in 5% non-fat dry 
milk/TBST for 1h at room temperature with constant agitation. The blotted membrane was 
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washed 5x5 min with TBST. Membrane was developed using Lumi-Light western blotting 
substrate. 
    
2.3.3  Fluorescamine Assay 
In the principle of this assay, fluorescamine reacts quantitatively with primary amines, 
forming a fluorescent product. The concentration of primary amines in TCA-soluble 
fractions reflects the rate of proteolysis of the substrate protein by the proteasome. In the 
experiment, 50 µl of histone samples oxidized with 0-1-5-10-15-20-30 mM H2O2 mixed 
with 25 µl nonoxidized nuclear extract (prepared as described in 2.2.1.2), 50 µl 2 mM 
NAD+ solution (for the samples without poly(ADP-ribosyl)ation H2O was added instead of 
NAD+) and 125 µl reaction buffer including 300 mM sucrose and 10 mM HEPES. The 
reaction mixture was incubated for 15 min at 37°C, centrifuged 720xg for 5 min. After 
centrifugation, 20.2 µl supernatant + 20 µl of 0.7 mg/ml isolated proteasome (provided 
from P.Voss) + 84.8 µl reaction buffer were mixed and incubated for 2h at 37°C with 350 
rpm shaking. 50 µl incubation solution + 450 µl ice-cold 10% TCA were incubated on ice 
for 30 min and centrifuged 3000xg for 10 min at 4°C. 250 µl fluorescamine solution (9 mg 
in 30 ml acetone) were added in 5 min intervals into the 125 µl supernatant + 625 µl 1M 
HEPES mixture. Following 5 min incubation of each samples in dark, fluorescence was 
measured at 390 nm excitation / 475 nm emission wavelength with a microplate reader. 
Glycine was used as a standard to determine amino acid liberation by proteolysis. 
Proteolysis rates were calculated as the difference between sample values and blank 
values. 
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2.3.4  Measurement of poly(ADP-ribosyl)ation of histones 
2.3.4.1  Liquid scintillation counting 
17 µl of histone samples oxidized with 0-1-5-10-15-20-30 mM H2O2 were mixed with 
167.5 µl reaction mixture, 0.5 µl PARP-1 enzyme, 10 µl DNA and 5 µl 14C-NAD+ , 
incubated for 10 min at 37°C. The reaction was stopped by addition of 0.8 ml of ice-cold 
20% TCA. After standing on ice for 30 min, samples were centrifuged 14000xg for 10 
min. Onto the pellet, 200 µl of solvable was added and following the solubilizing, 
radioactivity of samples were counted in scintillation cocktail. 
 
Reaction mixture 100 mM Tris-HCl + 10 mM MgCl2 + 5 mM DTT 
PARP-1 ready enzyme (human expressed in 
E.coli, Sigma P0396) 
12 µg / 20 µl  
DNA (from calf thymus, sigma D1501)  3.25 mg / 5 ml H2O            Sonicated 10 x 20s  
[carbonyl-14C]Nicotinamide adenine dinucleotide 
(GE Healthcare, CFA372) 
370 kBq, 10 µCi 
ULTIMA GOLD Scintillation cocktail  Perkin 
Elmer 6013327    
 
SOLVABLE Perkin Elmer 6NE9100   
 
Tab. 2.10     Solutions for poly(ADP-ribosyl)ation of histones by liquid scintillation counting 
 
2.3.4.2  Western blot 
50 µl of histone samples oxidized with 0-10-20 mM H2O2 mixed with 25 µl nonoxidized 
nuclear extract (prepared as described in 2.2.1.2), 50 µl 2 mM NAD+ (Sigma N8410) 
solution and 125 µl reaction buffer including 300 mM sucrose and 10 mM HEPES. The 
reaction mixture was incubated for 15 min at 37°C, centrifuged 720xg for 5 min. 45 µl of 
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supernatants mixed with 15 µl reducing Laemmli-buffer [0.25 M Tris pH 6.8, 8% SDS, 
40% glycerol, 0.03% bromophenol blue] and were denatured at 95 °C for 5 min and 
applied to SDS-PAGE of 7.5% (w/v) acrylamide, followed by electrophoresis and blotting 
onto nitrocellulose membrane according to standard procedures. Immunodetection was 
performed with the anti-poly(ADP-ribose) mouse monoclonal (Biomol) at 1:2000 dilution. 
After exposure to peroxidase-coupled secondary antibodies (Calbiochem), membranes 
were developed using Lumi-Light western blotting substrate (Cell Signaling). 
 
2.4   Aging effects on the model 
2.4.1  Cell culture  
Human foreskin fibroblasts were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with penicillin 100 U/ml, streptomycin 100 μg/ml and 10% fetal 
calf serum (FCS) in a humidified atmosphere of 5% CO2 and 95% air at 37 °C. 
Experiments were performed with cells of different population doubling numbers as 19+/-
4, 36+/-4, 56+/-3. 
 
2.4.2  Immunoblot analysis  
Nuclear extracts were prepared as described in 2.2.1.2 from different aged fibroblasts as 
PD 19+/-4, PD 36+/-4, PD 56+/-3. 20 μg of total protein in reducing Laemmli-buffer were 
denatured at 95 °C for 5 min and applied to SDS-PAGE of 12% (w/v) acrylamide for 
proteasome and of 7.5% (w/v) acrylamide for PARP-1, followed by electrophoresis and 
blotting onto nitrocellulose membrane according to standard procedures. 
Immunodetections were performed with the following antibodies: rabbit polyclonal anti-
PARP (Cell Signaling) at 1:1000 dilution, rabbit polyclonal anti-20S proteasome ‘core’ 
subunits (Biomol) at 1:1000 dilution, rabbit polyclonal anti-histone H4 (Cell Signaling) at 
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1:1000 dilution. After exposure to peroxidase-coupled secondary antibodies (Calbiochem), 
membranes were developed using Lumi-Light western blotting substrate (Cell Signaling).  
 
2.4.3  PARP activity measurement  
Different aged fibroblasts with PD 19+/-4, PD 36+/-4, PD 56+/-3 were seeded in 96-well 
plates and fixed in 10% ice-cold TCA (100 l/well) at -20oC for 10 minutes, then 
dehidrated by successive 10 min washes in 100l prechilled 70%, 96% and 100% ethanol 
at -20oC. After 3x5 min rinses with PBS, endogenous peroxidase activity was blocked by 
15 min incubation in 0.5% hydrogen peroxide/methanol. After washing with PBS, plates 
were blocked in 5% BSA in PBS-Triton X-100 for 60 min at 37oC. BSA solution was then 
aspirated and cells were incubated with monoclonal anti-poly(ADP-ribose) antibody 
diluted 1:5000 in 1% BSA/PBS- Triton X-100 for 2 h at 37oC. After three washes with 
PBS-Triton X-100, samples were incubated with peroxidase conjugated anti-mouse IgG 
(Calbiochem) diluted 1:300 in 1% BSA/PBS- Triton X-100 for 90 min at 37oC. Cells were 
then washed three times with PBS- Triton X-100 and reaction was developed with Amplex 
Red substrate. Fluorescence was measured at 530 nm excitation and 590 nm emission 
wavelength with a microplate reader.  
 
2.4.4  Proteasome activity measurement  
Different aged fibroblasts with PD 19+/-4, PD 36+/-4, PD 56+/-3 were treated with 0.5 
mM H2O2 for 0-5-15-30 min. Nuclear extracts were prepared as described in 2.2.1.2. 
Proteasome activity was analyzed in these supernatants as described in 2.2.3. 
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2.4.5 Poly(ADP-ribosyl)ation of proteasome  
Nuclear extracts were prepared as described in 2.2.1.2 from different aged fibroblasts as 
PD 19+/-4 and PD 56+/-3. 50 µl of isolated proteasome mixed with 25 µl nonoxidized 
nuclear extract, 50 µl 2 mM NAD+ solution and 125 µl reaction buffer including 300 mM 
sucrose and 10 mM HEPES. For some samples active PARP-1 was added instead of 
proteasome. The reaction mixture was incubated for 15 min at 37°C, centrifuged 720xg for 
5 min. Proteasome activity was analyzed in these supernatants as described in 2.2.3. 
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3     Results 
3.1    Results in cell culture 
3.1.1  MTT viability test 
To determine the concentrations and durations of H2O2 treatments in the experiments with 
HT22 cells, first a viability assay was performed. According to the results shown in 
Fig.3.1, 0.00-1.00 mM hydrogen peroxide with 30min duration (Fig.3.1.A) and 0-60 min 
durations with 1.00 mM concentration (Fig.3.1.B) did not cause any significant cell death 
which are not less than 75%. 
 
 
 
 
 
 
Fig. 3.1  Viability in different concentrations of H2O2 (A) and different durations of incubations (B). 
Incubation time for H2O2 in (A) 30 min, incubation concentration in (B) 1.00 mM H2O2. Controls were 
incubated only with PBS (+Ca&Mg) and shown as 100 % viable. (n=3, ANOVA, Bonferroni’s Multiple 
Comparison Test. Data are mean ±SEM). 
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3.1.2  Proteasome activity  
Proteasomal activity in HT22 cells was measured following H2O2 treatment of HT22 cells.  
Proteasomal degradation of the model proteasome peptide substrate suc-LLVY-MCA 
increased in a time and concentration dependent fashion . 
 
Because it is known that the nuclear proteasome can be stimulated by interaction with the 
PARP-1 in vitro, in lysates of hydrogen peroxide-treated isolated nuclei and in living cells 
[76-79], we used the specific PARP-1 inhibitors 3-ABA and PJ-34 and tested the effect of 
PARP-1 inhibition on proteasomal degradation in HT22 cells. 3-ABA and PJ-34 inhibited 
the induction of proteasome activation and these results proved the role of PARP-1 in the 
activation of proteasome.   
 
 
 
 
 
 
 
 
Fig. 3.2  20S proteasome activity in different concentrations of H2O2 (A), different durations of incubations 
(B) and the effects of PARP-1 inhibitors 3-ABA (0.5 M) and PJ-34 (40 µM) in the proteolytic activation of 
proteasome (C). Incubation concentration in (A) 1.00 mM H2O2, incubation time for H2O2 in (B and C) 30 
min. Controls were incubated only with PBS (+Ca&Mg). (n=3; *p<0.05 vs treated, &p<0.05 vs treated 
without inhibitors. ANOVA, Bonferroni’s Multiple Comparison Test. Data are mean ±SEM). 
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3.1.3 Immunoblot analysis 
Whole cell lysates and nuclear extracts of HT22 cells were analyzed for PARP-1 and 20S 
‘core’ proteasome protein expressions following H2O2 treatments. As seen in Fig.3.3 there 
was no change in protein expressions of PARP-1 and 20S proteasome both in whole cell 
lysates and nuclear extracts. This explains that the proteasome was activated only 
enzymatically without any change in the protein amount and PARP-1 protein amount was 
also not affected following oxidative damage in the cells. 
 
 
 
 
 
Fig. 3.3  Protein expressions in different time periods of 1mM H2O2 in whole lysates and nuclear extracts of 
HT22 cells. PARP-1 protein amounts (A), 20S proteasome subunit protein amount (B). Controls were 
incubated only with PBS (+Ca&Mg). 30 μg proteins were electrophoresed (SDS-PAGE gel) and 
immunoblotted with rabbit polyclonal anti-PARP1 antibody and  rabbit polyclonal anti-20S proteasome-core 
subunits antibody. 
 
3.1.4 qPCR analysis 
Following no significant change in protein amount of PARP-1, PARP-1 mRNA 
expressions were checked with quantitative PCR. Results showed that mRNA expression 
was increased in 30 and 40 min of 1.00 H2O2 treatment. 
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Fig. 3.4  The dose dependence of PARP-1 
mRNA expressions following 1.00 mM H2O2 
treatment. (n=3; *p<0.05 vs untreated, ANOVA, 
Bonferroni’s Multiple Comparison Test. Data are 
mean ± SEM) 
 
 
3.1.5 Protein carbonyls in cell lysates 
As an indicator of oxidized proteins the amount of protein-bound carbonyls were measured 
following H2O2 treatment according to Buss et al. [84]. The use of protein carbonyl groups 
as a biomarker of oxidative stress is widely accepted due to relative early formation and 
the stability of carbonylated proteins [86]. The protein carbonyl content of cells was 
enhanced with H2O2 treatment as seen at 0 time point in Fig.3.5, and the cells did recover 
within 3h after H2O2 treatment. With LC and 3-ABA pretreatment of the cells, the recovery 
from carbonyls was decreased. These results can be explained as follow: 1)The proteasome 
plays a major role in the degradation of oxidatively modified proteins. In this study, the 
increase in the activation of proteasome was shown in Fig.3.2.A-B following H2O2 
treatment. This proteasomal activity may cause the recovery from carbonyls and the 
inhibition of the proteasomal activity by specific 20S proteasome inhibitor LC caused a 
significant decline in the recovery. 2)As the second mechanism related to the first one is 
the activation of proteasomal degradation with poly(ADP-ribosyl)ation. Here also PARP-1 
enzyme was inhibited by 3-ABA pretreatment and also a significant decline in the recovery 
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from carbonyls was seen which confirms that the inhibition of PARP-1 also causes a 
decline in the proteasomal degradation.       
Fig. 3.5 Protein carbonyl recovery in different 
time points after H2O2 treatment and the effects 
of lactacystin (LC) and 3-aminobenzamide (3-
ABA) pretreatments on this recovery. (n=3; 
*p<0.05 vs time point 0, ANOVA, Bonferroni’s 
Multiple Comparison Test. Data are mean ± 
SEM) 
 
3.1.6 Comet assay and PARP activity  
Comet assay is a special analysis to determine the DNA damage especially DNA strand 
breaks. This test was performed to measure the oxidative DNA damage. In Fig.3.6.A, an 
increase in the oxidative DNA damage was shown as concentration dependent of H2O2. As 
shown in carbonyl recovery, there is also another mechanism to ensure the recovery from 
DNA damage and single strand breaks. In Fig.3.6.B there is a recovery from single strand 
breaks caused by H2O2. I thought that this recovery may be arised from both proteasomal 
degradation and PARP-1 activity. To confirm this, the cells were pretreated with LC, 3-
ABA and PJ-34 and all of them caused a slow down of DNA repair (Fig.3.6.C), which 
means proteasome and PARP inhibition caused a decline in the recovery. Since it is known 
that PARP is activated following DNA damage especially by single strand breaks, I also 
checked PARP activitation following H2O2 treatment and the effects of LC, 3-ABA and 
PJ-34 on this activation. In Fig.3.6.D one can see that PARP was activated following H2O2 
treatment. LC pretreatment did not affect this PARP activation confirming that LC inhibits 
only proteasomal activity. On the contrary, 3-ABA and PJ-34 strong inhibitors of PARP-1 
caused a decline in PARP activity. 
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Fig. 3.6 Comet assay and PARP cELISA analysis following H2O2 treatment in HT22 cells. Dose dependent 
DNA damage following H2O2 treatment. HT22 cells were treated with different concentrations of H2O2 for 30 
min (n=3; *p<0.05 vs untreated, ANOVA, Bonferroni’s Multiple Comparison Test. Data are mean ± SEM) 
(A). Recovery in single strand breaks in different time points after H2O2 treatment (n=3; *p<0.05 vs time 
point 0, ANOVA, Bonferroni’s Multiple Comparison Test. Data are mean ± SEM) (B). Recovery of DNA 
damage 3 h after H2O2 treatment and the effects of proteasome inhibitor lactacystin (LC), and PARP-1 
inhibitors 3-aminobenzamide (3-ABA) and PJ-34 on this recovery. Inhibitor pretreatments and following 
H2O2 treatment were done for 30 min (n=3; *p<0.05 vs control which was pretreated with PBS+Ca&Mg, 
ANOVA, Bonferroni’s Multiple Comparison Test. Data are mean ± SEM) (C). PARP activity changes 
following H2O2 treatment of HT22 cells and the effects of proteasome inhibitor lactacystin (LC), and PARP-
1 inhibitors 3-aminobenzamide (3-ABA) and PJ-34 on PARP activity. Inhibitor pretreatments and following 
H2O2 treatment were done for 30 min (n=3; *p<0.05 vs control which was not treated with H2O2, ANOVA, 
Bonferroni’s Multiple Comparison Test. Data are mean ± SEM) (D).  
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3.1.7 8-OHdG amounts 
8-Hydroxy-2’-deoxyguanosine (8-OHdG), one of the most abundant oxidative DNA 
adducts, is recognized as a useful marker for the estimation of DNA damage produced by 
oxygen radicals. Fig.3.7 shows that 0.4 mM H2O2 treatment caused an increase in the 8-
OHdG formation and this effect was declined with 3h incubation in medium showing the 
recovery. LC as proteasome inhibitor caused a decline in this 8-OHdG recovery which was 
also seen in Fig.3.6.C with single strand breaks. 
 
Fig. 3.7 The recovery in 8-OHdG formation 3h 
after H2O2 treatment of HT22 cells and the 
effect of lactacystin (LC) on this recovery. LC 
pretreatment and following H2O2 treatment were 
done for 30 min  (n=3; *P<0.05 vs time point 0, 
ANOVA, Bonferroni’s Multiple Comparison 
Test. Data are mean ± SEM) 
 
 
3.2 Results in isolated histones 
3.2.1 Fluorescamine Assay in isolated histones  
Histones are the most abundant nuclear proteins, and therefore the turnover of individual 
histones were measured. Because the proteasome is well known to be responsible for the 
degradation of oxidatively damaged proteins [23,24], we investigated the proteasomal 
contribution to the total histone degradation in the next set of experiments. After H2O2 
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treatment of HT22 cells, proteasomal degradation of oxidized histones increased 
significantly until 10 mM concentration and then decreased with the increased 
concentration. After reaching an optimum degree of oxidative damage at 10 mM, further 
damage decreased the proteolytic susceptibility of histone. With poly(ADP-ribosyl)ation of 
oxidized histones there was no change in the proteasomal degradation of histones 
(Fig.3.8.A). 
 
3.2.2 Measurement of poly(ADP-ribosyl)ation of histones 
As mentioned above, poly(ADP-ribosyl)ation is known to activate proteasome activity. On 
the other side histone-pADPr-PARP-1 complex is thought to be formed at the site of DNA 
lesion. Here poly(ADP-ribosyl)ation of unfractionated histones, provided from Sigma, was 
tested following oxidation. This can bring the idea into the mind that this complex 
formation may cause decrase in the histone degradation. As seen in Fig.3.8.A the 
proteasomal degradation of histones increased as H2O2 concentration dependent and with 
PAR of histones this degradation was declined to the basal level. Following this result we 
checked PAR of histones in the same conditions by scintillation counting and western blot 
and saw a decline in the PAR of histones as H2O2 concentration dependent. This decrease 
in the PAR of histones may be inducing the proteasomal degradation selectively for 
oxidized proteins. 
 
3.2.3 Protein carbonyl measurement in isolated histones 
Histones (provided from Sigma) were analyzed following the derivatization by DNPH for 
the detection of oxidative modifications by ELISA and western blot. As demonstrated in 
Fig.3.8.C, there was not such a high increase in the protein carbonyl formation with active 
proteasome in the nuclear extracts. 
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Fig. 3.8 Results in isolated histones. Histones were treated with different concentrations of H2O2 for 30 min. 
Susceptibility of oxidatively modified histones to proteolytic degradation by proteasome and the effect of 
poly(ADP-ribosyl)ation on this degradation. Proteolysis experiments were performed with the isolated 
proteasome from human erythrocytes (0.7 mg/ml), prepared according to Hough et al. [87], the damaged and 
nondamaged histones with and without poly(ADP-ribosyl)ation. Proteolytic degradation was measured using 
the fluorescamine assay and proteolysis is expressed as nanomoles of free amines generated per minute per 
mg of proteasome (n=3; *p<0.05 vs untreated, ANOVA, Bonferroni’s Multiple Comparison Test. Data are 
mean ± SEM) (A). Poly(ADP-ribosyl)ation of histones following H2O2 treatment. Tested both liquid 
scintillation counting and western blot (inset), mouse monoclonal anti-poly(ADP-ribose), product size 175-
225 kDa (n=3; *p<0.05 vs untreated, ANOVA, Bonferroni’s Multiple Comparison Test. Data are mean ± 
SEM) (B). Dose dependent protein carbonyl formation following H2O2 treatment. Tested both by ELISA and 
western blot (inset) (MW of the protein is 150 kDa) rabbit anti-DNP antibody for both procedure (n=3; 
*p<0.05 vs untreated, ANOVA, Bonferroni’s Multiple Comparison Test. Data are mean ± SEM) (C). 
 
3.3 Aging effects on the model 
This part of the thesis shows the changes in PARP-1 and proteasome in different aged 
fibroblasts with PD 19+/-4, 36+/-4, 56+/-3. PARP-1 and proteasome as nuclear protective 
mechanisms are assumed to be effected during senescence process. 
I want to thank E. Bakondi for her effort in this part.  
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3.3.1 Immunoblot analysis 
Protein amounts of PARP-1 and 20S ‘core’ proteasome subunit were tested in different 
aged fibroblasts. The results shown in Fig.3.9 indicate that aging causes a decrease in 
PARP-1 protein amount whereas does not change 20S proteasome protein amount. Histone 
H4 was analyzed to show the equal protein amount in the wells.   
  
Fig. 3.9 Protein expressions in the nucleus of 
different aged fibroblasts with population 
doubling (PD); 19+/-4, 36+/-4, 56+/-3. PARP-1 
was detected with rabbit polyclonal anti-PARP1 
 antibody and proteasome was detected with  
rabbit polyclonal anti-20S proteasome-core subunits antibody. Histone H4 was tested to show the equal 
protein amounts in the wells. (Experiments were performed by E. Bakondi).  
 
3.3.2 PARP activity changes in young and senescent fibroblasts 
PARP enzymatic activity was analyzed in different aged fibroblasts in 0-5-15-30 min time 
points following 0.5 mM H2O2 treatments. As shown in Fig. 3.10, PARP activity increased 
15 min after H2O2 treatment in young and middle-aged fibroblasts. This activation in 15 
min was not seen in old cells confirming the previous studies that shows the decrease in 
PARP-1 activity during aging. 
Fig. 3.10 PARP activity changes in the nucleus 
of different aged fibroblasts with population 
doubling (PD); 19+/-4, 36+/-4, 56+/-3 following 
0-5-15-30 min treatments of 0.5 mM H2O2. The 
results are shown as arbitrary fluorescence unit 
(AFU). (n=3; *p<0.05 vs time point 0, ANOVA, 
Bonferroni’s Multiple Comparison Test. Data are 
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mean ± SEM) (Experiments were performed by 
E.Bakondi)  
3.3.3 Proteasome activity changes in young and senescent fibroblasts 
Proteasome activity was analyzed in different aged fibroblasts in 0-5-15-30 min time 
points following 0.5 mM H2O2 treatments. As shown in Fig. 3.11, proteasome activity 
increased in all cells with H2O2 treatment.  
 
Fig. 3.11 20S proteasome activity in the nucleus 
of different aged fibroblasts with population 
doubling (PD); 19+/-4, 36+/-4, 56+/-3 following 
0-5-15-30 min treatments of 0.5 mM H2O2. The 
results are shown as arbitrary fluorescence unit 
(AFU). (n=3; *P<0.05 vs time point 0, ANOVA, 
Bonferroni’s Multiple Comparison Test. Data are 
mean ± SEM) (Thanks to E.Bakondi) 
  
 
3.3.4 Poly(ADP-ribosyl)ation of proteasome in young and senescent 
fibroblasts 
Proteasome activity was measured in young and old fibroblasts following different 
processes. In Fig.3.12.A, young cells had an increase in proteasome activity following 
poly(ADP-ribosyl)ation whereas old cells did not. In this process, active isolated 
proteasome was added into the reaction. In Fig.3.12.B, young and old cells both had an 
increase in proteasome activity following poly(ADP-ribosyl)ation. In this second process, 
active PARP-1 enzyme was added into the reaction. This shows the limiting role of PARP-
1 in the activation in old cells.  
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Fig. 3.12 The effect of PARP in the proteasomal activation in young and senescent fibroblasts. Nuclear 
extraction was done as described in Material and Method. Isolated proteasome was from Dr.Voss that was 
prepared according to Hough et al. PARP enzyme was obtained from Sigma. Poly(ADP-ribosyl)ation was 
achieved by the addition of NAD into the reaction.  Proteasome was added into the nuclear extracts of young 
and senescent fibroblasts (n=3; *P<0.05 vs without poly(ADP-ribosyl)ation, ANOVA, Bonferroni’s Multiple 
Comparison Test. Data are mean ± SEM) (A). PARP enzyme was added into the nuclear extracts of young 
and senescent fibroblasts  (n=3; *P<0.05 vs without poly(ADP-ribosyl)ation, ANOVA, Bonferroni’s 
Multiple Comparison Test. Data are mean ± SEM) (B).  
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4   Discussion 
4.1  Activation of the protesome by PARP-1 
Proteasome as the major proteolytic system responsible for the removal of oxidized 
proteins may be affected in a different manner during oxidative stress process. It might be 
activated by moderate oxidative damage parallel to sensitivity of moderately oxidized 
proteins to proteolytic attack and severely oxidized proteins are often poor substrates and 
might, however, inhibit the proteasome. In our model, proteasome was activated following 
H2O2 treatment which was in the concentration and duration range (Fig.3.1) without any 
significant cell death (Fig.3.2). This increase in the proteasome was not because the protein 
amount of proteasome increased as tested by immunoblotting (Fig.3.3). 
   
The 20S-proteasome is known to interact noncovalently with both poly(ADP-ribose) and 
automodified PARP-1 [8,80]. Interaction required long ADP-ribose polymers and caused a 
specific stimulation of the proteasome's peptidase activity. To examine the question if 
proteasome is activated by PARP, we performed experiments with 3-ABA and PJ-34, 
selective and strong inhibitors of PARP [88]. Incubation with both of these inhibitors, 
blocked the degradation of oxidized histones in nuclear lysates (Fig.3.2). 3-ABA and PJ-34 
are by far the best characterized and most commonly used inhibitors of PARP. Therefore 
we used these inhibitors in the bulk of the experiments. These results further support the 
proposal that PARP may be responsible for the rapid activation of nuclear proteasome 
during H2O2 exposure. In addition there was no change in the protein amount of PARP-1 in 
whole cell and nucleus following H2O2 treatment (Fig.3.3). In contrast PARP-1 mRNA 
levels increased in 30-40 min of 1.00 mM H2O2 treatment (Fig.3.4). This PARP-1 mRNA 
overexpression was shown to increase in various human malignancies, such as malignant 
 51 
 
lymphoma [89], breast carcinoma [90], Ewing’s sarcoma [91], hepatocellular carcinoma 
[92] and endometrial carcinoma [93]  as a consequence of oxidative stress.  
 
Also in previous studies, poly(ADP-ribosyl)ation has been shown to be a general nuclear 
response to oxidative stress [94]. It was demonstrated that DNA-single strand breaks 
(SSBs), which cause a significant PARP-1 activation after H2O2 treatment, are found 
shortly after H2O2 exposure and disappear subsequently due to nuclear repair mechanisms 
[95,96]. Thus, PARP-1 activation followed the appearance of SSBs and correlated well 
with the time course of proteasome activation. In this context, it has been demonstrated 
that the efficient repair of SSBs induced by γ-irradiation and H2O2 treatment requires 
PARP activity in rat germinal cells [97]. Moreover, PARP inhibition resulted in a strong 
accumulation of DNA damage in human leukaemia cells after adriamycin treatment [78].   
 
Ullrich et al. showed that histone proteins appear to be highly susceptible to oxidant-
induced proteolysis in intact cells. They also demonstrated the probable role of nuclear 
proteasome in histone turnover during oxidant stress with the experiments performed with 
the proteasome inhibitor lactacystin. Lactacystin completely suppressed the preferential 
proteolysis of oxidized histones without altering the degradation of nonoxidized histones, 
in lysates from both H2O2 treated nuclei and nontreated nuclei. They examined whether the 
20S proteasome itself is a substrate for poly(ADP ribosyl)ation by PARP and showed that 
H2O2 caused a time-dependent increase in nuclear proteasome activity, which was 
paralelled by an increasing incorporation of radioactivity derived from [14C]-NAD+ [8]. 
 
H2O2 is able to induce oxidative DNA damage, including SSBs in the nuclei of HT22 cells 
leading to the activation of the PARP enzyme (Fig.3.6). Furthermore tumor cells are 
known to have higher PARP activity and a higher basal poly-ADP ribose content than 
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normal cells [98], which could explain the strong activation of poly-ADP ribose synthesis 
in nuclei of HT22 cells after exposure to H2O2. Poly(ADP-ribosyl)ation is strongly related 
to DNA repair. PARP molecules bind tightly to DNA strand breaks and auto-poly(ADP-
ribosyl)ation of the protein then effects its release and allows access to lesions for DNA 
repair enzymes as shown by Ullrich et al. [76,77]. Binding of PARP to strand breaks may 
represent a signal that switches off DNA replication and transcription to ensure that lesions 
are not replicated before repair, and a ‘‘nick protection’’ during replication or cellular 
differentiation also has been proposed. The binding of PARP to DNA lesions and a strong 
activation after administration of various antitumor drugs has been reported in vitro. 
Increased poly-ADP ribosylation also has been suggested as an adaptive response of tumor 
cells to long-term antitumor drugs, which may be responsible for the development of 
chemotherapeutic resistance [5,88,98]. Thus the interaction between PARP and the nuclear 
proteasome may well play an important role in the secondary antioxidant defenses. 
 
By using the conditions of Banasik et al. [99] for in vitro poly(ADP-ribosyl)ation of 
proteins, we were indeed able to demonstrate the changes in the susceptibility of isolated 
histone proteins following PAR. This modification of histones caused a decrease in the 
proteasomal degradation of histones (Fig.3.8.A). Poly(ADP-ribosyl)ation is the shuttling of 
histones by detachment and reattachment of histones to chromatin through reversible poly-
ADP ribose synthesis and degradation [100]. 
 
In this study, we investigated the endogenous degradation of oxidatively damaged histones 
in HT22 mouse hippocampal cells after oxidative challenge and demonstrated a link to the 
overall cellular stress response pathways by poly-ADP-ribose-polymerase (PARP). After 
an oxidative challenge, endogenous nuclear protein degradation, as well as histone 
degradation, was enhanced. 
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4.2 Role of the proteasome in chromatin repair 
Histones are the main proteins in chromatin structure. In the nuclear oxidative damage 
(from metabolic free radical formation, ionizing radiation, xenobiotics, chemotherapy) 
besides the DNA oxidation, protein oxidation also takes an important place. For the protein 
oxidation, these histone structures are also a target. Due to long lifespan and low turnover 
rate of histones, proteolytic reactions are required to be highly selective and well regulated. 
For the turnover of histones, a distinct nuclear proteolytic system is required that brings 
proteasomal system into mind with the high specificity to degrade oxidized proteins. 
Degradation of oxidatively damaged histones provides the maintenance of chromatin 
integrity.  
 
Nucleosomal histones protect DNA from free radical mediated damage [70], and histone 
detachment and reattachment are closely connected with transcription and replication 
processes as with DNA repair and therefore requires functionally intact histones. 
Oxidatively damaged histones are able to cross-link with DNA and would impair the 
detachment-reassembly process [101]. As mentioned above, automodified PARP-1 
activates the proteasome to facilitate selective degradation of oxidatively damaged 
histones. Heteromodified histones might also lead to the activation of the proteasome [14]. 
Therefore, I studied the ability of the 20S proteasome to degrade damaged histones as a 
function of the extent of their oxidation. Data shown in Fig.3.8.A support the concept that 
mild oxidation exposes hydrophobic residues that render histones susceptible to 
degradation, whereas more extreme oxidation promotes hydrophobic aggregation, ionic 
bonds and covalent crosslinks all of which diminish proteolytic susceptibility. This effect 
has already been described for a number of cytosolic proteins by several groups 
[23,24,102,103]. In my model system I found a decline in proteolytic degradation of 
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poly(ADP-ribosyl)ated histones. In the same content Ullrich et al. found a decrease in 
proteolytic degradation in histones bound to DNA [71]. 
 
Protein carbonyl formation following histone oxidation was also tested in this model and 
was not seen such a high increase in the carbonyl formation [Fig.3.8.C]. This prevention in 
the carbonyl formation was thought to be as a consequence of the increase in proteolytic 
degradation. Oxidation of histones was performed for 2h with the nuclear extract, and this 
duration is thought to be sufficient for oxidized histones to be degraded and prevents the 
accumulation of carbonylated proteins. 
 
8-OHdG, one of the most abundant oxidative DNA adducts, is used as an indicator of 
oxidative DNA damage [104]. In the nuclear repair process, following a time point of 
oxidative damage, damage products are expected to be decreased by several systems. In 
Fig.3.7 this repair mechanism following 3h after H2O2 treatment was confirmed to be 
proteasome dependent which was effected by selective proteasome inhibitor LC. 
 
Besides all, for the efficiency of chemotherapeutic treatment, closer insights into the 
cellular defense mechanisms of tumor cells are required. The cytotoxic action of 
anthracyclines by the generation of free radicals has been demonstrated both in vitro and in 
vivo [5,105,106]. However, such an antioxidative defense system might also be used by 
certain leukemia cells to cope with nuclear damages induced by radical-producing 
compounds. Consequently, these resistant leukemia cells survive chemotherapy and 
potentially develop a tumor relapse.  Previous studies have demonstrated an elevated 
proteasome activity in leukemia cells and a possible relationship to the proliferative 
activity [107]. Also PARP enzyme was demonstrated to be highly activated by 
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chemotherapy treatment [26]. In this context also studies have suggested that PARP 
inhibition modulates chemotherapy toxicity [108-110].  
 
Each of these functions implies important roles for nuclear proteasome in the chromatin 
repair activated by PARP enzyme.  
      
4.3 The protesome-PARP-activation in the senescence process 
Accumulation of oxidized proteins and a loss of activity of the proteolytic enzymes, 
including the proteasome, are highlights of age-related changes of cellular metabolism. 
This accumulation of protein oxidation products might be the result of a reduction of the 
efficacy of the removal of oxidized proteins or the result of an increased oxidant 
production. Merker et al. concluded that proteasomal concentration in the nucleus is not 
changing during the senescence process [111]. The result in Fig.3.9 is consistent with this 
conclusion and does not show any proteasome amount change in different aged fibroblasts 
with the PD 19+/-4, 36+/-4, 56+/-3.  
  
The protective functions of PARP-1 discussed above and also its reported role in 
maintaining telomere length in mice [112] are in line with the previously observed 
correlation of cellular poly(ADP-ribosyl)ation capacity and life span of mammalian 
species, whereby the longest-lived species studied (man) displayed 5-fold the level of 
maximal PARP activity of the shortest-lived (rat), while PARP-1 protein levels in the two 
species were identical [53]. In analyses of the automodification reaction, human PARP-1 
displayed up to 2-fold higher activity. Therefore differences at the level of primary 
structure of PARP-1 do appear to modulate specific enzyme activity, but this does not fully 
account for the longevity-related differences in cellular poly(ADP-ribosyl)ation capacity 
mentioned above. Probably, interaction of PARP-1 with other proteins plays a role. 
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PARP activity has also been investigated in nuclear fractions from various regions of rat 
brain as a function of age [113]. In old animals, PARP activity in the hippocampus was 
found to be lowered by about 50%, but unchanged in cerebral cortex and in cerebellum, 
compared to adult rats. It was proposed that the lower enzyme activity in aged 
hippocampus might underlie the higher vulnerability of neurones to various toxic insults in 
old animals.  
 
An age-dependent decline of cellular poly(ADPribosyl)ation capacity had previously also 
been found in lymphocytes from rat and man [53], and ADPRT gene expression was 
recently reported to be downregulated in proliferating fibroblasts from old human donors 
and from progeria patients compared to normal young donors [114]. Viewed together, 
various pieces of evidence from a variety of systems and experimental approaches are now 
converging in support of a close link between poly(ADP-ribosyl)ation and the control of 
the ageing process. 
 
Chevanne et al. tested PARP-1 and PARP-2 mRNA expressions in B lymphocyte cells 
from young subjects, old subjects and centenarians. They investigated the relationship 
between DNA repair capacity and PARP activity in these cell lines. Data showed that cells 
from centenarians have characteristics in poly(ADP-ribosyl)ation capacity, while in cells 
from old subjects these phenomena are delayed or decreased. Moreover, cells from old 
subjects showed a constitutive expression level of both parp 1 and parp 2 genes reduced 
by a half, together with a reduced presence of modified PARP-1 and other poly(ADP-
ribosyl)ated chromatin proteins in comparison to cells from young subjects and 
centenarians. They support the hypothesis that this epigenetic modification is an important 
regulator of the aging process in humans and it appears to be rather preserved in healthy 
centenarians, the best example of successful aging [115].  
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In the results of this study, this repair mechanism in senescent cells following oxidative 
damage was shown to decrease by several experiments. In the immunoblot of PARP-1, a 
decrease was seen by the increase of the population doublings of the fibroblasts whereas 
there was no change in the proteasome amount. In Fig.3.10, PARP activity was increased 
following H2O2 treatment in young and middle aged cells and there was no change in 
PARP activation in senescent cells. Meantime, proteasome activitation increased in all 
young, middle aged and old cells compared to untreated cells following H2O2 treatment. 
But proteasome activity was found to be less in middle aged and old cells compared to 
young cells. To confirm all these results, one other experiment was done with young and 
old nuclear extracts (Fig.3.12). When active proteasome was added into the reaction 
together with nuclear extracts, proteasome was activated in young cells but not in old cells 
following poly(ADP-ribosyl)ation and when active PARP was added into the reaction 
together with nuclear extracts both in young and old cells, there was an increase in the 
proteasome activities following poly(ADP-ribosyl)ation. This shows that PARP is the 
limiting factor for the induction of proteasome activity. 
 
4.4 Outlook into future research 
In view of the above mentioned prominent role of PARP-1 related activation of 
proteasomal degradation in tumour cell lines, there is obviously a significant potential of 
PARP inhibitory substances with appropriate pharmacokinetic profiles as drugs to improve 
the chemotherapeutic treatment. It will be interesting to see the effects in animal models 
and clinical studies. 
 
The availability of new tools, such as cell lines deficient in PARPs will contribute greatly 
to the future understanding of the complex and fascinating functions of poly(ADP-
ribosyl)ation in living cells. Using PARP-1 knockout cells, one might expect an 
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accumulation of oxidative modified proteins and DNA-protein cross links due to reduced 
proteasome activation and thus a delay in proteolysis of damaged proteins after oxidative 
stress should be expected. 
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5    Conclusion  
The above discussed experimental findings indicate that the nuclear proteasome selectively 
degrades oxidatively damaged histones in the nuclei of mammalian cells, where it is 
activated and regulated by the automodified PARP-1 after oxidative challenge. The 
interaction of poly-(ADP-ribosyl)ated PARP-1 and the 20S proteasome represents a novel 
and unique regulatory mechanism that might link together two different nuclear secondary 
antioxidant defense systems—DNA repair and removal of damaged nucleoproteins, thus 
allowing restitution of the native chromatin structure and maintenance of genomic integrity 
under oxidative stress conditions [14]. 
 
As previously reported for cytosolic proteins [23,102], oxidative challenge also altered the 
turnover of endogenous nuclear proteins, demonstrating an enhanced protein degradation 
in nuclei after hydrogen peroxide treatment. Estimating the importance of this process for 
normal genome structure and function, tumor cells seem to be well endowed with nuclear 
proteases, preventing the nucleus from accumulation of erroneously folded proteins. 
 
Because numerous antitumor drugs act via the oxidation of nuclear material in the tumor 
cell, it is important to know how effectively and precisely tumor cells can cope with 
nuclear protein oxidation in addition to oxidatively induced DNA damage. Because the 
proteasomal system as well as the poly(ADP-ribosyl)transferase are involved in the 
effective and selective removal of oxidized proteins in the nucleus, one may suggest 
further treatment strategies to effectively interfere with the protein repair and replacement 
strategies of tumor cells. 
 
As another perspective, besides  tumor cells PARP-1 related activation of proteasome was 
found to be higher in young fibroblasts compared to old ones. This difference brings a new 
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point to focus in senescence process. Since this repair is less efficient in senescent cells, 
age related diseases may appear as a consequence and in the clinic this mechanism may be 
helpful for the efficient treatment. 
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Summary 
  
Poly(ADP-ribosyl)ation reactions are of interest in recent years and they take place in DNA 
repair in different processes especially following oxidative nuclear damage. Proteasomal 
reactions also take place in repair following oxidative nuclear damage with the degradation of 
oxidized histones. 
  
Antitumor chemotherapy is generally believed to act via the oxidation of nuclear material in 
the tumor cells. Adaptation to oxidative stress appears to be one element in the development 
of long-term resistance to many chemotherapeutic drugs. The 20S proteasome has been 
shown to be largely responsible for the degradation of oxidatively modified proteins in the 
nucleus. Tumor cells are supposed to have a higher nuclear proteasome activity than do 
nonmalignant cells. Poly(ADP-ribosyl)ation reactions take place in the tumor cells as a 
consequence of chemotherapy. Such a reaction might occur with the 20S proteasome –which 
is known to increase the activity- and also with histones –which is firstly shown to decrease 
the degradation in this study. After hydrogen peroxide treatment of HT22 cells, degradation of 
the model peptide substrate suc-LLVY-MCA and degradation of oxidized histones in nuclei 
increased accompanied by an increase in PARP-1 mRNA expression. In the recovery of the 
level of protein carbonyls, single strand breaks and 8-OHdG, proteasome and PARP-1 were 
shown to play a role together. This was tested with inhibitor treatments. The proteasomal 
activation following poly(ADP-ribosyl)ation of proteasome and the decrease in poly(ADP-
ribosyl)ation of histones and increase in the proteasomal degradation of histones following 
H2O2 treatment confirmed our hypothesis.  
The second part of the thesis shows the changes in PARP-1 and proteasome in different aged 
fibroblasts with population doublings 19, 36, and 56. The nuclear protective mechanisms 
  79 
were shown to be effected during the senescence process. PARP-1 protein amount decreased 
whereas there was no change in proteasome amount. PARP activation following H2O2 
treatment increased only in young and middle aged cells.  In the nuclear extracts of young and 
old cells, poly(ADP-ribosyl)ation potentials were tested with NAD+ addition into the reaction. 
In addition to that active proteasome and PARP enzymes were added into the reaction and 
proteasome activity was measured. With active PARP, proteasome activity was increased 
both in young and old cells whereas there was no increase in old cells without PARP addition. 
These results show that proteasome activation is mainly limited by PARP activity.  
 
Taken together all results demonstrate the importance of PARP mediated proteasome 
activation in the repair of oxidatively damaged chromatin. 
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Zusammenfassung 
 
Poly(ADP-ribosyl)ierungs-Reaktionen sind seit einigen Jahren im Zentrum des 
wissenschaftlichen Interesses. Sie finden während der DNA-Reparatur, insbesondere nach 
oxidativer Schädigung des Zellkerns statt. Proteasomale Reaktionen treten ebenfalls nach 
nukleärem Schaden auf und beinhalten den Abbau oxidierter Histone.  
 
Eine Antitumor-Chemotherapie wirkt in Tumorzellen häufig über die Oxidation nukleärem 
Materials. Eine Adaptation zu oxidativem Stress ist häufig ein Bestandteil der Entwicklung 
von Langzeit-Resistenzen gegen viele Chemotherapeutika. Es wurde häufig gezeigt, dass das 
20S Proteasom für den Abbau oxidativ modifizierter Proteine im Zellkern verantwortlich ist. 
Tumorzellen haben eine höhere nukleäre Proteasomaktivität als nichtmaligne Zellen. 
Poly(ADP-ribosyl)ierungsreaktionen finden im Zellkern als eine Konsequenz der 
Chemotherapie statt. Solch eine Reaktion erfolgt auch mit dem 20S Proteasom – gefolgt von 
einer Erhöhung der Aktivität- und auch mit Histonen, mit der Konsequenz eines reduzierten 
Abbau, wie in dieser Studie erstmals gezeigt. Nach einer Wasserstoffperoxidbelastung von 
HT22-Zellen steigt der Abbau des Modellpeptides suc-LLVY-MCA und von oxidierten 
Histonen im Zellkern – begleitet von einem Anstieg der PARP-1 mRNA. Die 
Wiederherstellung des Spiegels der Proteincarbonyle, der Einzelstrangbrüche und des 8-
OHdG setzt eine Interaktion von PARP-1 und des Proteasoms voraus. Dieses wurde mit 
Inhibitor-Studien untersucht. Die proteasomale Aktivierung nach Poly(ADP-ribosyl)ierung 
und der Abfall einer Poly(ADP-ribosyl)ierung der Histone sowie ein Anstieg des 
Histonabbaus nach H2O2–induziertem Stress, bestätigten diese Hypothese. 
Der zweite Teil der Arbeit beschäftigt sich mit der Veränderung der PARP-1 und des 
Proteasoms während der Fibroblastenalterung. Es wurden Zellen mit den 
Populationsverdopplungen 19, 36 und 56 untersucht. Die nukleären Schutzmechanismen 
waren vom Seneszenzprozess beeinflusst. Der PARP-1-Proteingehalt fiel, während das 
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Proteasom konstant blieb. Wasserstoffperoxid induzierte eine PARP-Aktivität nur in jungen 
und mittelalten Zellen. In nukleären Extrakten von jungen und alten Zellen wurde das 
Poly(ADP-ribosyl)ierungs-Potential nach NAD+ Zugabe gemessen. Zusätzlich wurden aktives 
Proteasom und PARP hinzugegeben und die Proteasomaktivität gemessen. Nach Addition 
von aktiver PARP ist die proteasomale Aktivität in jungen und alten Zellen angestiegen, 
wobei es zu keinem Anstieg in alten Zellen ohne PARP-Addition gab. Diese Untersuchungen 
zeigen, dass die proteasomale Aktivierung im wesentlichen durch die PARP-Aktivierung 
limitiert ist. 
 
Zusammengefasst zeigen meine Resultate die Wichtigkeit der PARP-vermittelten 
proteasomalen Aktivierung in der Reparatur oxidativ geschädigten Chromatins. 
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